Back to search

Article

Effects of immunorelated gene polymorphisms on trastuzumab targeting breast cancer cell

2023-10-18

Abstract excerpt

<h4>Purpose: </h4> Transtuzumab-based immunotherapy has been the standard of care for HER2/neu-expressing breast cancer (BC). However, only 20–30% of patients overexpressing HER2 respond to trastuzumab. This study aimed to investigate the associations between genetic polymorphisms in immunorelated genes and PBMC-induced cytotoxicity to breast cancer cell with the treatment of trastuzumab. <h4>Methods: </h4> Trastu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
efd94fad-b733-5c57-aac0-b66170c68237
DOI
10.21203/rs.3.rs-3447830/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Effects of immunorelated gene polymorphisms on trastuzumab targeting breast cancer cellDOI 10.21203/rs.3.rs-3447830/v1
Effects of immunorelated gene polymorphisms on trastuzumab targeting breast cancer cell in vitro.Semantic proximity
Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.Semantic proximity
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.Semantic proximity
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.Semantic proximity
The IFN-Ɣ + 874 A/T polymorphism is associated with malignant breast cancer in a population from the southwest of Iran.Semantic proximity
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.Semantic proximity
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.Semantic proximity
FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.Semantic proximity
Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma.Semantic proximity
Single Nucleotide Polymorphism Directed Antiemetic Treatment in Women With Breast Cancer Treated With Neo- or Adjuvant Chemotherapy: A Randomised Multicentre Phase II Study. (EudraCT: 2015-000658-39).Semantic proximity
Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.Semantic proximity
Cytotoxic T-lymphocyte antigen 4 polymorphisms and breast cancer susceptibility: Evidence from a meta-analysis.Semantic proximity
Select a neighboring publication to make it the new centre.